CD274 and hepatocellular carcinoma: In the combination dose-escalation cohorts: four confirmed responses, one unconfirmed response, and four patients had SD (≥6 months)In anti–PD-1/PD-L1 relapsed/refractory UC EXP cohort: five confirmed responses, one unconfirmed response, and five SDIn anti–PD-1/PD-L1–naïve HCC expansion cohort: five confirmed responses and three SD